Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 25;15(15):3778.
doi: 10.3390/cancers15153778.

The Use of Parenteral Opioids in Cancer Pain Management

Affiliations

The Use of Parenteral Opioids in Cancer Pain Management

Sebastiano Mercadante. Cancers (Basel). .

Abstract

Opioids should be offered to patients with moderate-to-severe pain related to cancer or active cancer treatment unless contraindicated. Although oral administration of opioids is generally preferable, a parenteral route may be advisable and mandatory in some clinical circumstances. Parenteral administration of opioids may accelerate the achievement of analgesia. The intravenous route fits the need of rapid achievement of analgesia in patients poorly responsive to other opioids and provides a fast analgesia in patients with breakthrough pain, that has a specific temporal pattern requiring a rapid analgesic effect. When the oral route is unavailable for the presence of nausea, vomiting, or dysphagia. the parenteral route is one of the principal options. Opioids have different pharmacokinetic and pharmacodynamic characteristics and should be chosen according to the individual needs. Thus, the knowledge and experience with these routes of administration are mandatory for anesthesiologists committed to cancer pain management.

Keywords: cancer pain; intravenous morphine; palliative care; parenteral opioids.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Example of rapid dose titration with intravenous morphine in an opioid-tolerant patient with poor pain control.

Similar articles

References

    1. Snijders R.A.H., Brom L., Theunissen M., van den Beuken-van Everdingen M.H.J. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers. 2023;1:591. doi: 10.3390/cancers15030591. - DOI - PMC - PubMed
    1. Mercadante S. Cancer Pain Treatment Strategies in Patients with Cancer. Drugs. 2022;82:1357–1366. doi: 10.1007/s40265-022-01780-6. - DOI - PubMed
    1. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. World Health Organization; Geneva, Switzerland: 2018. - PubMed
    1. Paice J.A., Bohlke K., Barton D., Craig D.S., El-Jawahri A., Hershman D.L., Kong L.R., Kurita G.P., LeBlanc T.W., Mercadante S., et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J. Clin. Oncol. 2023;41:914–930. doi: 10.1200/JCO.22.02198. - DOI - PubMed
    1. Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11:484–489. doi: 10.1016/S1470-2045(09)70350-X. - DOI - PubMed

LinkOut - more resources